1. A UK Real-world Evaluation of Efficacy and Toxicity of Second-line Trastuzumab Emtansine and Third-line Trastuzumab Deruxtecan in HER2-positive Advanced Breast Cancer. Issue 6 (June 2023) Authors: Peters, S.; Tang, H.C.; Shafiq, T.; Karim, S.; Khan, S.; Trivedi, S.; Anand, A.; Sheikh, H.B.; Saghir, S.; Lui, J.; Prabhu, D.S.; Mathew, T.; Rakha, E.A.; Madhusudan, S. Journal: Clinical oncology Issue: Volume 35:Issue 6(2023) Page Start: e419 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Palbociclib or Ribociclib with Aromatase Inhibitor in Post-menopausal Women with ER+/HER2– Advanced Breast Cancer? Real-world Overall Survival Evidence. Issue 6 (June 2023) Authors: Tang, H.K.C.; De Souza, K.; Ahmad, O.; Shafiq, T.; Khan, S.; Anand, A.; Karim, S.; Trivedi, S.; Rahka, E.A.; Madhusudan, S. Journal: Clinical oncology Issue: Volume 35:Issue 6(2023) Page Start: e420 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗